{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:09:43Z","timestamp":1788858583728,"version":"build-2803163510"},"reference-count":46,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Comprehensive Evaluation of Pharmaceuticals, Zhejiang Pharmaceutical Association","award":["2024ZYYL14"],"award-info":[{"award-number":["2024ZYYL14"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to explore the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on weight changes and the occurrence of adverse reactions in overweight or obese adults after drug withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Computerized searches were conducted in evidence-based databases such as PubMed, Embase, Cochrane Library and Scopus. The search period was from the establishment of the database to December 2025. Collect randomised controlled trials (RCTs) and controlled trials on GLP-1RAs, including tirzepatide, semaglutide, liraglutide, and dulaglutide, for the treatment of overweight or obese adult patients. The risk of bias in the included studies was assessed using the Cochrane Risk of Bias V2.0 tool provided by the Cochrane Collaboration, and meta-analysis was performed using the R programming language.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 699 studies were initially retrieved. Eventually, six studies involving 8,993 patients were included in the quantitative analysis, comprising 5,553 patients in the discontinuation group and 3,440 in the continued treatment group. The results of the meta-analysis showed that, compared with the continued treatment group, the weight difference in the discontinuation group was mean difference (MD) = 17.90%, 95% confidence interval (CI) [14.11\u201321.69],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001. It can be seen that there was a significant rebound in weight after drug withdrawal, and there was statistical heterogeneity among the studies (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0082). Subgroup analysis further revealed that the weight rebound amplitude after discontinuation of tirzepatide was significantly higher than that of semaglutide. This result suggests that the differences in the mechanism of action of different GLP-1RAs may be the reason for the differences in weight changes after discontinuation. In addition, the percentage difference in body weight between after and before drug withdrawal was MD = 9.11%, 95% CI [7.91\u201310.30],\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001, further verifying the trend of weight rebound after drug withdrawal. The summary of adverse reaction reports analyzed and studied indicates that after drug withdrawal, the overall adverse reactions of patients decreased, gastrointestinal adverse reactions decreased, and the incidence of cardiovascular events was not affected by drug withdrawal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a significant weight rebound phenomenon after discontinuation of GLP-1RAs, and the rebound magnitudes vary among different types of drugs. At the same time, there is a risk of adverse reactions during the use of such drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.21713","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:34:51Z","timestamp":1788856491000},"page":"e21713","source":"Crossref","is-referenced-by-count":0,"title":["Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis"],"prefix":"10.7717","volume":"14","author":[{"given":"Huaji","family":"Qi","sequence":"first","affiliation":[{"name":"Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou,  Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou,  Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou,  Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Du","sequence":"additional","affiliation":[{"name":"Hangzhou Linping District Integrated Traditional Chinese and Western Medicine Hospital, Hangzhou,  Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobo","family":"Pan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Ningbo No.2 Hospital, Wenzhou Medical University, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"Suppl 1","key":"10.7717\/peerj.21713\/ref-1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1002\/oby.23086","article-title":"Describing the weight-reduced state: physiology, behavior, and interventions","volume":"29","author":"Aronne","year":"2021","journal-title":"Obesity"},{"issue":"1","key":"10.7717\/peerj.21713\/ref-2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"Journal of the American Medical Association"},{"issue":"8","key":"10.7717\/peerj.21713\/ref-3","doi-asserted-by":"publisher","first-page":"e13929","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obesity Reviews"},{"issue":"20","key":"10.7717\/peerj.21713\/ref-4","doi-asserted-by":"publisher","first-page":"e010951","DOI":"10.1161\/JAHA.118.010951","article-title":"Change in cardiometabolic risk factors associated with magnitude of weight regain 3 years after a 1-year intensive lifestyle intervention in type 2 diabetes mellitus: the look AHEAD trial","volume":"8","author":"Berger","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"2","key":"10.7717\/peerj.21713\/ref-5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/dom.15360","article-title":"Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study","volume":"26","author":"Chen","year":"2024","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"3","key":"10.7717\/peerj.21713\/ref-6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"Journal of Lipid and Atherosclerosis"},{"issue":"3","key":"10.7717\/peerj.21713\/ref-7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"6","key":"10.7717\/peerj.21713\/ref-8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1152\/japplphysiol.00049.2025","article-title":"Increasing the health span: unique role for exercise","volume":"138","author":"Gaesser","year":"2025","journal-title":"Journal of Applied Physiology"},{"issue":"10402","key":"10.7717\/peerj.21713\/ref-9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.7717\/peerj.21713\/ref-10","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"issue":"9","key":"10.7717\/peerj.21713\/ref-11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"issue":"11","key":"10.7717\/peerj.21713\/ref-12","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/oby.70011","article-title":"Tirzepatide associated with improved health-related quality of life in adults with obesity or overweight in SURMOUNT-4","volume":"33","author":"Gibble","year":"2025","journal-title":"Obesity"},{"issue":"5","key":"10.7717\/peerj.21713\/ref-13","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC202405210","article-title":"Obesity","volume":"177","author":"Gilden","year":"2024","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.7717\/peerj.21713\/ref-14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial","volume":"186","author":"Horn","year":"2026","journal-title":"JAMA Internal Medicine"},{"issue":"8","key":"10.7717\/peerj.21713\/ref-15","doi-asserted-by":"publisher","first-page":"156366","DOI":"10.1016\/j.jand.2026.156366","article-title":"Mind the plateau: a mathematical modeling analysis of long-term GLP-1 receptor agonist treatment","volume":"126","author":"Hubert","year":"2026","journal-title":"Journal of the Academy of Nutrition and Dietetics"},{"issue":"5","key":"10.7717\/peerj.21713\/ref-16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/ijo.2014.177","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2015","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.7717\/peerj.21713\/ref-17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.21713\/ref-18","doi-asserted-by":"publisher","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.7717\/peerj.21713\/ref-19","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1038\/s41467-022-32307-y","article-title":"Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment","volume":"13","author":"Jensen","year":"2022","journal-title":"Nature Communications"},{"key":"10.7717\/peerj.21713\/ref-20","doi-asserted-by":"publisher","first-page":"1366940","DOI":"10.3389\/fendo.2024.1366940","article-title":"The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study","volume":"15","author":"Jensterle","year":"2024","journal-title":"Frontiers in Endocrinology"},{"issue":"5","key":"10.7717\/peerj.21713\/ref-21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver International"},{"issue":"6707","key":"10.7717\/peerj.21713\/ref-22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","article-title":"GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans","volume":"385","author":"Kim","year":"2024","journal-title":"Science"},{"issue":"10","key":"10.7717\/peerj.21713\/ref-23","doi-asserted-by":"publisher","first-page":"e46490","DOI":"10.7759\/cureus.46490","article-title":"Effect on Hemoglobin A1c (HbA1c) and body weight after discontinuation of tirzepatide, a novel glucose-dependent insulinotropic peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor agonist: a single-center case series study","volume":"15","author":"Kubota","year":"2023","journal-title":"Cureus"},{"key":"10.7717\/peerj.21713\/ref-24","doi-asserted-by":"publisher","first-page":"116150","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"24","key":"10.7717\/peerj.21713\/ref-25","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.7717\/peerj.21713\/ref-26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-8587(26)00037-9","article-title":"Is weight cycling clinically harmful?","volume":"14","author":"Magkos","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.7717\/peerj.21713\/ref-27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/oby.23481","article-title":"Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial","volume":"30","author":"Maselli","year":"2022","journal-title":"Obesity"},{"issue":"24","key":"10.7717\/peerj.21713\/ref-28","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 Receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"Journal of the American Medical Association"},{"key":"10.7717\/peerj.21713\/ref-29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"American Journal of Cardiology"},{"issue":"21","key":"10.7717\/peerj.21713\/ref-30","doi-asserted-by":"publisher","first-page":"e984\u2013e1010","DOI":"10.1161\/CIR.0000000000000973","article-title":"American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council, Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"8008","key":"10.7717\/peerj.21713\/ref-31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/d41586-024-01091-8","article-title":"Obesity drugs aren\u2019t always forever. What happens when you quit?","volume":"628","author":"Prillaman","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.7717\/peerj.21713\/ref-32","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies","volume":"14","author":"Quarenghi","year":"2025","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.7717\/peerj.21713\/ref-33","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 Receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Network Open"},{"issue":"13","key":"10.7717\/peerj.21713\/ref-34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 Receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"10077","key":"10.7717\/peerj.21713\/ref-35","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le\u00a0Roux","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.7717\/peerj.21713\/ref-36","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.15148","article-title":"Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison","volume":"25","author":"le\u00a0Roux","year":"2023","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"14","key":"10.7717\/peerj.21713\/ref-37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"Journal of the American Medical Association"},{"issue":"17","key":"10.7717\/peerj.21713\/ref-38","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.7717\/peerj.21713\/ref-39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.7717\/peerj.21713\/ref-40","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.7717\/peerj.21713\/ref-41","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"31","key":"10.7717\/peerj.21713\/ref-42","doi-asserted-by":"publisher","first-page":"E875\u2013E891","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Canadian Medical Association Journal\/Journal de L\u2019Association Medicale Canadienne"},{"issue":"11","key":"10.7717\/peerj.21713\/ref-43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.7717\/peerj.21713\/ref-44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"9","key":"10.7717\/peerj.21713\/ref-45","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/oby.23842","article-title":"Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity","volume":"31","author":"Wilkinson","year":"2023","journal-title":"Obesity"},{"key":"10.7717\/peerj.21713\/ref-46","author":"World Obesity\u00a0Federation","year":"2025","journal-title":"World Obesity Atlas 2025"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/21713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21713.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21713.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:34:54Z","timestamp":1788856494000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/21713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":46,"alternative-id":["10.7717\/peerj.21713"],"URL":"https:\/\/doi.org\/10.7717\/peerj.21713","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"e21713"}}